PAM
IMMU

Peak Asset Management’s Immunomedics Inc IMMU Stock Holding History

Peak Asset Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-14,526
Closed -$196K – 135
2020
Q1 		$196K Buy
+14,526
New +$244K 0.08% 106

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Peak Asset Management's IMMU Position: Q2 2020 in Review

Peak Asset Management sold out of Immunomedics Inc (IMMU) in Q2 2020, closing a stake of 14,526 shares — an estimated $196K sold.

Peak Asset Management first reported a position in IMMU in Q1 2020 and held it in 1 quarter. The position peaked at $196K in Q1 2020. 313 funds tracked by Wall St. Rank hold IMMU as of Q2 2020.

  • Peak Asset Management reported no remaining Immunomedics Inc position as of Q2 2020 after selling out during the quarter.
  • Peak Asset Management sold 14,526 Immunomedics Inc shares in Q2 2020, an estimated $196K.
  • Peak Asset Management first reported a position in Immunomedics Inc in Q1 2020 and held it in 1 quarter.
  • Peak Asset Management's Immunomedics Inc position peaked at $196K in Q1 2020.
  • 313 funds tracked by Wall St. Rank held Immunomedics Inc as of Q2 2020.

Based on Peak Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.